Teva VP Ika Abravanel resigns
"Radio Europe 1": French health authorities found that Teva's heart medication could only have been repackaged by human intervention.
French language "Radio Europe 1" reports that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) believes that product tampering is behind the switching of packages of its heart failure medication Furosemide with the sleeping pill Zopiclone, after no breakdown was found in the Furosemide production line. "Radio Europe 1" adds that Teva will file a complaint about the incident.
"Radio Europe 1" says that, in the past two days, France's National Agency for the Safety of Medicines and Health Products (MSNA) investigated the plant where Furosemide is produced, and concluded that it was not possible to switch the packaging without deliberate human intervention.
"Radio Europe 1" says that Teva therefore concludes that this is a case of malicious tampering.
On Sunday, it was reported that MSNA ordered Teva to recall two batches of Furosemide 40 mg tablets, a prescription drug. The packaging of the drug in packages of Zopiclone has reportedly caused the death of several patients and the hospitalization of others. Teva said in response, "Teva has welcomed a report from the ANSM, the French regulatory body, following an inspection at the company’s packaging site in Sens, France, after which the agency said that its preliminary findings did not identify any faults in the organization, practices or the equipment at the site.
"Teva continues to conduct its internal investigation and to open and inspect blisters of furosemide Teva 40mg (diuretic). At this time, none of the blisters of furosemide 40mg we have opened contained a zoplicone tablet. Teva France has apologized for any inconvenience to its patients, and the company will work to complete its review as soon as possible. Other markets and other Teva France products are not affected by the recall."
"Some media reports have linked at least one patient death in France to this issue. Teva has expressed its sorrow to hear of the death of any patient, but the company has not at this time received any evidence that this was connected to the recalled product; and is cooperating fully with the authorities in their investigations," Teva concluded.
Published by Globes [online], Israel business news - www.globes-online.com - on June 12, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.